PLX..$9.60 Solid 8-K regarding the Interim results from the switchover trial. This data clearly supports the safety and maintenance of efficacy of taliglucerase alfa. This should give the FDA additional support to approve the drug for Gaucher's Disease.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.